Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in R/R MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate, which is scheduled to be evaluated 6 months from the completion of enrollment.  This global study, conducted by Janssen has completed enrollment of the planned 110 patients in April of 2013.
  • Phase Ib dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive B-cell Non Hodgkin Lymphoma (DLBCL, MCL, FL). The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP. With a recommended Phase II dose established, the study is currently in the expansion phase in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, has been fully accrued. An update on the dose escalating phase of this study will be provided at ASCO, 2013.
  • Phase II study of ibrutinib in patients with R/R MM. This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in patients with R/R MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. Pharmacyclics anticipates an update on this program will be provided by year end 2013.
  • Phase II study of ibrutinib in patients with R/R follicular lymphoma (FL). This is a multi-center, global study of ibrutinib in patients with chemoimmunotherapy-resistant FL, whose disease has relapsed from at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen. The primary endpoint of this study is ob
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
    (Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
    (Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
    Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
    ... Aug. 9, 2011 Styron, the global materials ... announced an addition to its EMERGE™ Advanced Resins ... 9100CR Advanced Resin is a polycarbonate blend ... medical equipment housing applications. (Logo: http://photos.prnewswire.com/prnh/20110809/CL49820LOGO) ...
    ... Aug. 9, 2011 Enox Biopharma, Inc., a leader ... hospital acquired infections today announced on line publication of ... E.coli on the surface of nitric oxide releasing devices ... The paper was published by Professor Yossef Av-Gay,s lab ...
    Cached Medicine Technology:Styron Introduces Chemical Resistance Blends for Medical Housings 2Comparative Study Confirms Enox Biopharma's Antimicrobial Superiority to Commercially Available Silver Coated Catheters 2
    (Date:7/13/2014)... 2014 Hope Palliative & Hospice Care announced ... group at the Tamarack Senior Living Community in Palatine, IL. ... A.M. on the 3rd Wednesdays of every month. This ... Tamarack Community located at 55 S. Greeley St. Palatine, IL ... there is no cost for the group. , “A ...
    (Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, iFitDress.com, ... and women’s special occasion outfits, has added a new ... website. Furthermore, the company has launched a promotion for ... discount. , iFitDress.com is now providing thousands of ... products sell well in Britain, America, France, Italy and ...
    (Date:7/12/2014)... July 12, 2014 The Chicken ... the past five years, buoyed by stable demand for ... management system. “Eggs are a relatively affordable staple for ... egg consumption generally grows in line with the size ... McKitterick. Furthermore, demand for new specialty egg products with ...
    (Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester ... – Trends & Forecast to 2018," defines and segments ... volume and value. The report also estimates the demand ... phthalic anhydride is projected to grow from an estimated ... with a CAGR of 5.24% from 2013 to 2018. ...
    (Date:7/12/2014)... 2014 Demand Response Management Systems is ... in reducing the imbalance between energy supply and demand. ... been rolled out (due to increasing pressure on the ... helps in controlling residential appliances and thermostats for load ... North American region, and with government mandates and benefits ...
    Breaking Medicine News(10 mins):Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4
    ... treated with stimulant medications rather than nonstimulant medications ... medications, such as mixed amphetamine salts (MAS) and ... nonstimulant medications such as modafinil. ,This conclusion ... studies representing the past 25 years of research ...
    ... issued a notice to the Centre asking it to ... implement 27 per cent reservation was taken//. ,With ... Court today decided to examine the government's controversial move ... economically backward classes in higher educational institutions. ...
    ... junior doctors here who have been protesting the central ... backward classes have sought// President A.P.J. Abdul Kalam's permission ... the president seeking his "permission to immolate themselves", informed ... ,Four of the junior doctors sitting on a ...
    ... 3 years woke up after being administered a sleeping pill, ... hit the research table for thorough clinical testing. , ... tested on 30 patients during the course of this year, ... of coma. After the initial success, the pill has been ...
    ... by which 15% of Americans were suffered, was caused ... there's often little left// to do but to suffer ... flatulence make their lives miserable, limiting some of their ... basic of treatments is lifestyle modification instead of taking ...
    ... the death toll rising to over 3500 and an incalculable ... on scale, Indonesia struggles// to cope with the injured and ... in the south of the city of Yogyakarta which is ... the Friday night. The earthquake left the city in shambles, ...
    Cached Medicine News:Health News:Stimulant Medications More Effective In Treating ADHD Than Nonstimulants 2Health News:Supreme Court Verdict Gives Hope to Striking Medicos 2Health News:Silence Puts Comfort For Digestive Syndrome 2Health News:Indonesian Earthquake – Story of Destruction, Death and Disease 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: